Investigational Drug Details
| Drug ID: | D263 |
| Drug Name: | Phenformin |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00914 |
| DrugBank Description: | A biguanide hypoglycemic agent with actions and uses similar to those of metformin. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290) |
| PubChem ID: | 8249 |
| CasNo: | 114-86-3 |
| Repositioning for NAFLD: | Yes |
| SMILES: | NC(=N)NC(=N)NCCC1=CC=CC=C1 |
| Structure: |
|
| InChiKey: | ICFJFFQQTFMIBG-UHFFFAOYSA-N |
| Molecular Weight: | 205.2596 |
| DrugBank Targets: | 5'-AMP-activated protein kinase catalytic subunit alpha-1; ATP-sensitive inward rectifier potassium channel 8 |
| DrugBank MoA: | Phenformin binds to the AMP-activated protein kinase (AMPK). AMPK is an ultra-sensitive cellular energy sensor that monitors energy consumption and down-regulates ATP-consuming processes when activated. The biguanide phenformin has been shown to independently decrease ion transport processes, influence cellular metabolism and activate AMPK. Phenformin's hypoglycemic activity is related the effect it has in activating AMPK and fooling insulin sensitive cells into thinking that insulin levels are low and causing the body to use glucose as if in a state of low caloric consumption. This drug also seems to inhibit several varients of ATP-sensitive potassium channels (namely the receptor subtype Kir6.1). |
| DrugBank Pharmacology: | Used to treat diabetes, phenformin is a biguanide (contains 2 guanidino groups) hypoglycemic agent with actions and uses similar to those of metformin (Glucophage). Both drugs work by (1) decreasing the absorption of glucose by the intestines, (2) decreasing the production of glucose in the liver, and by (3) increasing the body's ability to use insulin more effectively. More specifically, phenformin improves glycemic control by improving insulin sensitivity. Phenformin is generally considered to be associated with an unacceptably high incidence of actic acidosis. In general biguanides should be used only in stable type II diabetics who are free of liver, kidney and cardiovascular problems and who cannot be controlled with diet. |
| DrugBank Indication: | For the reatment of type II diabetes mellitus. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|